Home
ICCM
ICCM News

Latest IceCure Medical Ltd. (ICCM) News on September 18, 2025

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

PR Newswire

10 days ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

MT Newswires

3 months ago

Sector Update: Health Care Stocks Softer Wednesday Afternoon

MT Newswires

3 months ago

IceCure Medical's Board Approves $10 Million Rights Offering

IceCure Announces Record Date for Rights Offering for Up to $10 Million

PR Newswire

3 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

PR Newswire

3 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ...

GuruFocus.com

4 months ago

Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ...

IceCure Medical Reports First Quarter 2025 Financial Results

PR Newswire

4 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

Icecure Medical Ltd (ICCM) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

4 months ago

Icecure Medical Ltd (ICCM) Q1 2025: Everything You Need To Know Ahead Of Earnings

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

PR Newswire

4 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

PR Newswire

4 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

PR Newswire

5 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

PR Newswire

5 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

PR Newswire

5 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

Zacks

6 months ago

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

IceCure Medical Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

6 months ago

IceCure Medical Full Year 2024 Earnings: Misses Expectations

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

PR Newswire

6 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

PR Newswire

6 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

PR Newswire

6 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

MT Newswires

6 months ago

IceCure Medical Expects FDA Decision on ProSense After Q1

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

PR Newswire

6 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

PR Newswire

6 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

MT Newswires

6 months ago

IceCure Gets Notice of Allowance from China's Intellectual Property Regulator

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

PR Newswire

6 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

PR Newswire

6 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure seeks Israeli regulatory approval for XSense cryoablation system

Medical Device Network

7 months ago

IceCure seeks Israeli regulatory approval for XSense cryoablation system

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

PR Newswire

7 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

Simply Wall St.

7 months ago

IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

PR Newswire

7 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure submits application to China’s NMPA for cryoablation system approval

Medical Device Network

8 months ago

IceCure submits application to China’s NMPA for cryoablation system approval

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

PR Newswire

8 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

PR Newswire

8 months ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing

Simply Wall St.

8 months ago

The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

PR Newswire

8 months ago

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

MT Newswires

8 months ago

IceCure Says European Patent Office Issues Intention to Grant Notice for Cryoablation System

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

PR Newswire

8 months ago

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

PR Newswire

9 months ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

PR Newswire

9 months ago

IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

10 months ago

IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

Zacks

10 months ago

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

PR Newswire

10 months ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

PR Newswire

10 months ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

PR Newswire

10 months ago

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

PR Newswire

10 months ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

IceCure’s cryoablation system for breast cancer treatment gains FDA panel support

Medical Device Network

10 months ago

IceCure’s cryoablation system for breast cancer treatment gains FDA panel support

PR Newswire

10 months ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

PR Newswire

a year ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

PR Newswire

a year ago

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

Alignment HealthCare Partners With Intermountain Health in Nevada

Zacks

a year ago

Alignment HealthCare Partners With Intermountain Health in Nevada

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

PR Newswire

a year ago

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Zacks

a year ago

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

PR Newswire

a year ago

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

PR Newswire

a year ago

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

PR Newswire

a year ago

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

PR Newswire

a year ago

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

PR Newswire

a year ago

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

PR Newswire

a year ago

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

PR Newswire

a year ago

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

PR Newswire

a year ago

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

PR Newswire

a year ago

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

IceCure presents hat-trick of positive trial data for cryoablation device

Medical Device Network

a year ago

IceCure presents hat-trick of positive trial data for cryoablation device

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

PR Newswire

a year ago

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

IceCure Medical receives Nasdaq compliance notice

Medical Device Network

a year ago

IceCure Medical receives Nasdaq compliance notice

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

PR Newswire

a year ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

Zacks

a year ago

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

PR Newswire

a year ago

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

Zacks

a year ago

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

FDA grants marketing authorisation for IceCure’s XSense Cryoablation System

Medical Device Network

a year ago

FDA grants marketing authorisation for IceCure’s XSense Cryoablation System

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

PR Newswire

a year ago

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

Simply Wall St.

a year ago

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

PR Newswire

a year ago

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

PR Newswire

a year ago

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

Zacks

a year ago

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

PR Newswire

a year ago

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

PR Newswire

a year ago

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

PR Newswire

a year ago

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

PR Newswire

a year ago

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year

Simply Wall St.

a year ago

Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

PR Newswire

a year ago

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

Zacks

a year ago

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

PR Newswire

a year ago

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

PR Newswire

a year ago

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

PR Newswire

a year ago

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

PR Newswire

a year ago

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

PR Newswire

a year ago

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

PR Newswire

2 years ago

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

PR Newswire

2 years ago

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

PR Newswire

2 years ago

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop

PR Newswire

2 years ago

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer

PR Newswire

2 years ago

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

PR Newswire

2 years ago

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

Associated Press Finance

2 years ago

Unifi: Fiscal Q2 Earnings Snapshot

UNIFI®, Makers of REPREVE®, Announces Second Quarter Fiscal 2024 Results

Business Wire

2 years ago

UNIFI®, Makers of REPREVE®, Announces Second Quarter Fiscal 2024 Results

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

PR Newswire

2 years ago

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

TEAF Announces 2023 Fund Tax Characterization of Distributions, Release of Annual Report

ACCESSWIRE

2 years ago

TEAF Announces 2023 Fund Tax Characterization of Distributions, Release of Annual Report

Associated Press Finance

2 years ago

Penns Woods: Q4 Earnings Snapshot

GuruFocus.com

2 years ago

Penns Woods Bancorp Inc (PWOD) Reports Mixed Results Amid Rising Interest Rates

Penns Woods Bancorp, Inc. Reports Fourth Quarter and Year Ended 2023 Earnings

GlobeNewswire

2 years ago

Penns Woods Bancorp, Inc. Reports Fourth Quarter and Year Ended 2023 Earnings

Share on Social Networks: